Antiviral Compounds with Broad Neutralization Capabilities


The NIH is pleased to announce as available for licensing a technology that provides for novel antiviral compounds effective against a broad spectrum of viruses. The compounds utilize soluble phospholipases, exemplified by PLA2-X and others, either alone or as a fusion protein with a viral binding polypeptide. These compositions are able to inactivate viruses through enzymatic degradation of the viral membrane without affecting target cells of infection. The potential broad application of these compounds could address a significant health need for effective antivirals.

Potential Commercial Applications: Competitive Advantages:
This technology provides compositions and methods for the treatment of viral infection and has human and veterinary applications. The compounds described by the current technology are not necessarily specific for a type of virus or viral strain like many currently available antiviral compounds, and therefore have broad therapeutic antiviral applications. Further, virions resistant to damage by antibody and complement have been shown to be lysed by compounds of the invention suggesting antiviral surveillance independent of a humoral immune response.


Development Stage:
Proof of concept in vitro studies using human cells have shown antiviral activity with viruses’ pseudotyped with envelope proteins from Ebola, HIV, Marburg and MoMuLV.

Inventors:

Gary Nabel (NIAID)  ➽ more inventions...

Jae Ouk Kim (NIAID)  ➽ more inventions...


Intellectual Property:
US Pat: - issued -
PCT Application No. PCT/US2007/004471 filed on 2007-02-21
02/17/2021 - Appln 12/224,273 is dead

Publications:
J-O Kim et al. Lysis of human immunodeficiency virus type 1 by a specific secreted human phospholipase A2. J Virol. 2007 Feb;81(3):1444-1450. PubMed abs

Licensing Contact:
Carol Salata, Ph.D.
Email: csalata@mail.nih.gov
Phone: 240-627-3727

OTT Reference No: E-013-2006-1
Updated: Feb 17, 2021